OBJECTIVE: To determine the effectiveness of treatment with conjugated equine estrogens (CEE) or with CEE combined with progestin (CEE + P) on age-related macular degeneration (AMD). METHODS: In an ancillary study to the Women's Health Initiative clinical trial of hormone therapy, 4262 women 65 years and older underwent fundus photography for the determination of AMD. Participants were recruited from April 2000 to June 2002 at 21 clinical sites an average of 5 years after randomization. Participants were randomized to treatment with CEE, CEE + P, or placebo. Participants had been treated for an average of 5 years at the ophthalmic evaluation for AMD. RESULTS: The overall prevalence of any AMD was 21.0%. No association was found between CEE + P (odds ratio [OR], 0.91; 95% confidence interval [CI], 0.75-1.11) or CEE alone (OR, 0.98; 95% CI, 0.78-1.25) and early-stage AMD. The CEE + P was associated with a reduced risk of soft drusen (OR, 0.83; 95% CI, 0.68-1.00) after adjustment for covariates and with a reduced risk of neovascular AMD (OR, 0.29; 95% CI, 0.09-0.92). CONCLUSIONS: Treatment with CEE alone or CEE + P does not affect early- or late-stage AMD. Treatment with CEE + P may reduce the risk of soft drusen or neovascular AMD.
RCT Entities:
OBJECTIVE: To determine the effectiveness of treatment with conjugated equine estrogens (CEE) or with CEE combined with progestin (CEE + P) on age-related macular degeneration (AMD). METHODS: In an ancillary study to the Women's Health Initiative clinical trial of hormone therapy, 4262 women 65 years and older underwent fundus photography for the determination of AMD. Participants were recruited from April 2000 to June 2002 at 21 clinical sites an average of 5 years after randomization. Participants were randomized to treatment with CEE, CEE + P, or placebo. Participants had been treated for an average of 5 years at the ophthalmic evaluation for AMD. RESULTS: The overall prevalence of any AMD was 21.0%. No association was found between CEE + P (odds ratio [OR], 0.91; 95% confidence interval [CI], 0.75-1.11) or CEE alone (OR, 0.98; 95% CI, 0.78-1.25) and early-stage AMD. The CEE + P was associated with a reduced risk of soft drusen (OR, 0.83; 95% CI, 0.68-1.00) after adjustment for covariates and with a reduced risk of neovascular AMD (OR, 0.29; 95% CI, 0.09-0.92). CONCLUSIONS: Treatment with CEE alone or CEE + P does not affect early- or late-stage AMD. Treatment with CEE + P may reduce the risk of soft drusen or neovascular AMD.
Authors: Sharon J Elliot; Paola Catanuto; Diego G Espinosa-Heidmann; Pedro Fernandez; Eleut Hernandez; Peter Saloupis; Kenneth Korach; Michael Karl; Scott W Cousins Journal: Exp Eye Res Date: 2009-09-30 Impact factor: 3.467
Authors: Digna R Velez Edwards; Paul Gallins; Monica Polk; Juan Ayala-Haedo; Stephen G Schwartz; Jaclyn L Kovach; Kylee Spencer; Gaofeng Wang; Anita Agarwal; Eric A Postel; Jonathan L Haines; Margaret Pericak-Vance; William K Scott Journal: Invest Ophthalmol Vis Sci Date: 2009-11-20 Impact factor: 4.799
Authors: Thasarat Sutabutr Vajaranant; Joelle Hallak; Mark A Espeland; Louis R Pasquale; Barbara E Klein; Stacy M Meuer; Stephen R Rapp; Mary N Haan; Pauline M Maki Journal: Am J Ophthalmol Date: 2019-06-01 Impact factor: 5.258
Authors: M Haan; M A Espeland; B E Klein; R Casanova; S A Gaussoin; R D Jackson; A E Millen; S M Resnick; J E Rossouw; S A Shumaker; R Wallace; K Yaffe Journal: Neurology Date: 2012-03-14 Impact factor: 9.910
Authors: Barbara E K Klein; Kerri P Howard; Sudha K Iyengar; Theru A Sivakumaran; Kristin J Meyers; Karen J Cruickshanks; Ronald Klein Journal: Invest Ophthalmol Vis Sci Date: 2014-08-14 Impact factor: 4.799
Authors: Ronald Klein; Karen J Cruickshanks; Scott D Nash; Elizabeth M Krantz; F Javier Nieto; Guan H Huang; James S Pankow; Barbara E K Klein Journal: Arch Ophthalmol Date: 2010-06
Authors: Richard J Santen; D Craig Allred; Stacy P Ardoin; David F Archer; Norman Boyd; Glenn D Braunstein; Henry G Burger; Graham A Colditz; Susan R Davis; Marco Gambacciani; Barbara A Gower; Victor W Henderson; Wael N Jarjour; Richard H Karas; Michael Kleerekoper; Roger A Lobo; JoAnn E Manson; Jo Marsden; Kathryn A Martin; Lisa Martin; JoAnn V Pinkerton; David R Rubinow; Helena Teede; Diane M Thiboutot; Wulf H Utian Journal: J Clin Endocrinol Metab Date: 2010-06-21 Impact factor: 5.958